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The myeloproliferative neoplasms, including polycythemia vera,essential thrombocythemia and myelofibrosis, are distinguishedby their debilitating symptom profiles, life-threatening complica-
tions and profound impact on quality of life. The role gender plays in
the symptomatology of myeloproliferative neoplasms remains under-
investigated. In this study we evaluated how gender relates to patients’
characteristics, disease complications and overall symptom expression.
A total of 2,006 patients (polycythemia vera=711, essential thrombo-
cythemia=830, myelofibrosis=460, unknown=5) were prospectively
evaluated, with patients completing the Myeloproliferative Neoplasm-
Symptom Assessment Form and Brief Fatigue Inventory Patient
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ABSTRACT
Introduction
The myeloproliferative neoplasms (MPN) have a repu-
tation for molecular complexity, clinical heterogeneity
and profound impact on duration and quality of life.
Polycythemia vera (PV), essential thrombocythemia (ET)
and myelofibrosis (MF) are debilitating MPN associated
with arterial and venous thrombosis, cytopenias, marked
splenomegaly, persistent constitutional symptoms and a
predilection for transformation into acute myelogenous
leukemia or MF (in ET and PV). 
There is emerging interest in understanding how gender
affects the development of MPN as well as the manifesta-
tions and progression of the disease. As exemplified by the
higher prevalence of females with ET and males with PV,
it has long been recognized that males and females may be
affected differently. However, recent literature supports
the potential for gender to influence genotypic expression
and, potentially, clonal expansion. For example, an inves-
tigation of gene expression in circulating CD34+ cells from
19 JAK2V617F-positive PV patients found that fewer genes
were differentially expressed in females (235 genes) than
in males (571 genes), but that more than three times as
many molecular pathways were activated in females.1
Females also have dramatically lower JAK2V617F allele bur-
dens.2,3 Furthermore, it has been shown that there are
female-dominant MPN clusters (both PV and ET) typified
by a high prevalence of laboratory abnormalities and sex-
uality-related complaints.4
Despite these new insights, little is known about how
gender relates to symptom profiles. The timely develop-
ment of MPN-specific Patient Reported Outcome (PRO)
tools has allowed us to objectively quantify MPN symp-
tom burden and evaluate the impact of this disease on
quality of life. The Myelofibrosis Symptom Assessment
Form (MF-SAF), Myeloproliferative Neoplasm Symptom
Assessment Form (MPN-SAF) and MPN-10 have been
applied in both clinical and trial settings, yielding signifi-
cant insights into how observed clinical and sympto-
matic heterogeneity may, in fact, follow predictable pat-
terns and/or harbor otherwise unrecognized associa-
tions. In this study, we examine associations between
gender and patients’ symptomatology, along with dis-
ease features, laboratory abnormalities and overall quali-
ty of life. 
Methods
Survey development and collection 
This study was approved by the Mayo Clinic
Institutional Review Board. Data were collected from an
international cohort of patients with MPN including ET,
PV and MF. All patients were recruited using the methods
described previously during the validation of the MPN-
SAF.5 The development and validation of the MPN-SAF
PRO are described in the Online Supplementary Appendix.
The language translation process is also detailed in the
Online Supplementary Appendix and was based on stan-
dard PRO translation methods.6 In addition to the MPN-
SAF, subjects also completed the Brief Fatigue Inventory
(BFI).7 Data were collected in various languages: English,
Dutch, Italian, French, German, Chinese, Swedish and
Spanish. Gender was recorded based on patients’ self-
reporting under the question of ‘sex’ with respondent
options of ‘male’ or ‘female’.  Evaluation of
cultural/regional variations in symptom expression
involved comparisons of Chinese patients with ‘Western’
patients, who were predominantly Caucasian individuals
from western Europe and the USA.
Symptom evaluation
Symptoms listed in the MPN-SAF included the
patient’s perceptions of common MPN-related symp-
toms and overall quality of life on a scale from 0 (absent)
to 10 (worst imaginable). The symptoms assessed includ-
ed items related to sadness, quality of life, inactivity, con-
centration problems, abdominal pain/discomfort, dizzi-
ness, insomnia, night sweats, worst fatigue, early satiety,
bone pain, numbness, cough, itching, headache, fever
and weight loss. Total symptom score was computed
based on ten symptom items. For individuals completing
at least six of the ten MPN-SAF total symptom score
items, the survey was scored by multiplying the average
score across items by ten to obtain a scaled score from 0
to 100.
Prognostic scoring
A prognostic score for ET was calculated using the
International Prognostic Scoring for Essential
Thrombocythemia (IPSET) system.8 This scoring system,
which includes the variables of leukocyte count
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Reported Outcome tools. Information on the individual patients’ characteristics, disease complications
and laboratory data was collected. Consistent with known literature, most female patients were more
likely to have essential thrombocythemia (48.6% versus 33.0%; P<0.001) and most male patients were
more likely to have polycythemia vera (41.8% versus 30.3%; P<0.001). The rate  of thrombocytopenia
was higher among males than females (13.9% versus 8.2%; P<0.001) and males also had greater red-
blood cell transfusion requirements (7.3% versus 4.9%; P=0.02) with shorter mean disease duration (6.4
versus 7.2 years, P=0.03). Despite there being no statistical differences in risk scores, receipt of most ther-
apies or prior complications (hemorrhage, thrombosis), females had more severe and more frequent
symptoms for most individual symptoms, along with overall total symptom score (22.8 versus 20.3;
P<0.001). Females had particularly high scores for abdominal-related symptoms (abdominal pain/dis-
comfort) and microvascular symptoms (headache, fatigue, insomnia, concentration difficulties, dizzi-
ness; all P<0.01). Despite complaining of more severe symptom burden, females had similar quality of
life scores to those of males. The results of this study suggest that gender contributes to the heterogene-
ity of myeloproliferative neoplasms by influencing phenotypic profiles and symptom expression.
≥11x109/L (1 point), age ≥60 years (2 points), and history
of thrombosis (1 point), was used to stratify patients into
different risk groups: low risk (0 points), intermediate
risk (1-2 points) and high risk (3-4 points). 
The prognostic score for survival of patients with PV
was calculated using the Leukemia 2013 prognostic scor-
ing model.9 This scoring system includes the variables of
age ≥67 years(5 points), age 57-66 years (2 points), prior
thrombosis (1 point) and leukocyte count ≥15x109/L (1
point) to stratify patients into low-risk (0 points), inter-
mediate risk (1-2 points) and high-risk (≥3 points) groups. 
The prognostic score for survival in patients with MF
was calculated using the Dynamic International
Prognostic Scoring System (DIPSS).10 This scoring model
includes the variables of hemoglobin <10 g/dL (2 points),
age ≥65 years (1 point), white blood cell count ≥25x109/L
(1 point), the presence of constitutional symptoms (1
point) and ≥1% blasts (1 point) to stratify patients into
low-risk (0 points), intermediate-1-risk (1-2 points), inter-
mediate-2-risk (3-4 points) and high-risk (>4 points)
groups.
Statistical analysis
All comparisons of patients’ symptoms were adjusted
for type of MPN and age. Continuous variables were
compared using analysis of variance and dichotomous
data were compared using the chi-square test. Statistical
significance was set at P<0.05. SAS version 9.3 (Cary,
NC, USA) was used for the analyses.
Results
Patients’ demographics
A total of 2,006 patients (917 males, 1,089 females)
with MPN completed the MPN-SAF and BFI (Table 1).
MPN subtypes included PV (n=711), ET (n=830) and MF
[n=460; primary MF (68.3%); post-ET MF (18%); post-
PV MF (13.7%)]. Patients were of the expected age (mean
59.9 years; range, 15-94) for their disorders and consisted
primarily of Chinese (27.1%) and French (23.0%) speak-
ers. When separated by DIPSS risk categories, most MF
patients were stratified as intermediate-1 risk (54.5%),
followed by intermediate-2 risk (24.3%), low risk
(18.3%) and high risk (3%). Most ET patients were strat-
ified as intermediate risk (46.7%), followed by low risk
(36.0%) and high risk (17.3%). For PV, most patients
were in the high-risk category (49.5%), followed by
intermediate-risk (29.7%) and low-risk (20.7%) cate-
gories. The mean hemoglobin concentration (13.4 g/dL,
SD 3.17), white blood cell count (8.9x109/L, SD 7.15), and
platelet count (429.5x109/L, SD 269.72) were evaluated,
along with laboratory abnormalities including anemia
(present in 8.5%), thrombocytopenia (present in 10.7%)
and leukopenia (present in 10.0%). Prior thrombosis
(21.2%) and prior hemorrhage (5.4%) were relatively
uncommon and most patients (94.0%) did not require
red blood cell transfusions.
Clinical factors
When comparing clinical factors between genders,
female patients were found to be slightly younger (59.3
versus 60.7 years, P=0.02) with more patients under the
age of 60 at the time of data collection (48.9% versus
43.4%, P=0.01; Table 1). The prevalence of MPN sub-
types also differed by gender (P=0.01) with more females
having a diagnosis of ET (48.6%) than of PV (30.3%) and
MF (21.2%) and more male patients having a history of
PV (41.8%) than of ET (33.0%) and MF (25.2%). Gender
distribution also differed by MPN subtype with primary
Table 1. MPN patients’ demographics by gender.
Females Males Total
(n=1089) (n=917) (n=2006) P-value
Mean age (range), years 59.3 (14.36) 60.7 (12.64) 59.9 (13.61) 0.02
Age <60 years 532 (48.9%) 397 (43.4%) 929 (46.4%) 0.01
MPN subtype (n, %) <0.001
ET 528 (48.6%) 302 (33.0%) 830 (41.5%)
PV 329 (30.3%) 382 (41.8%) 711 (35.5%)
MF 230 (21.2%) 230 (25.2%) 460 (23.0%)
MF (n, %) 0.01
Primary MF 142 (61.7%) 172 (74.8%) 314 (68.3%)
ET-MF 50 (21.7%) 33 (14.3%) 83 (18%)
PV-MF 38 (16.5%) 25 (10.9%) 63 (13.7%)
Mean MPN duration 7.2 (7.0) 6.4 (6.5) 6.8 (6.9) 0.03 
(years, SD)
Language (n, %) 0.19
Chinese 292 (26.8%) 252 (27.5%) 544 (27.1%)
Dutch 118 (10.8%) 118 (12.9%) 236 (11.8%)
English 75 (6.9%) 82 (8.9%) 157 (7.8%)
French 257 (23.6%) 205 (22.4%) 462 (23%)
German 72 (6.6%) 41 (4.5%) 113 (5.6%)
Italian 103 (9.5%) 83 (9.1%) 186 (9.3%)
Spanish 112 (10.3%) 82 (8.9%) 194 (9.7%)
Swedish 60 (5.5%) 54 (5.9%) 114 (5.7%)
MF DIPSS risk (n, %) 0.55
Low 24 (20.7%) 19 (16.0%) 43 (18.3%)
Intermediate-1 64 (55.2%) 64 (53.8%) 128 (54.5%)
Intermediate-2 24 (20.7%) 33 (27.7%) 57 (24.3%)
High 4 (3.4%) 3 (2.5%) 7 (3%)
ET IPSET risk (n, %) 0.11
Low 176 (37.8%) 86 (32.7%) 262 (36%)
Intermediate 218 (46.9%) 122 (46.4%) 340 (46.7%)
High 71 (15.3%) 55 (20.9%) 126 (17.3%)
PV risk (n, %) 0.30
Low 49 (19.1%) 66 (22.1%) 115 (20.7%)
Intermediate 71 (27.7%) 94 (31.4%) 165 (29.7%)
High 136 (53.1%) 139 (46.5%) 275 (49.5%)
Anemia 78 (8.4%) 66 (8.7%) 144 (8.5%) 0.84
(Hb<10 g/dL) (n, %)
Leukopenia 91 (9.9%) 77 (8.7%) 168 (10.0%) 0.83
(WBC<10x109/L) (n, %)
Thrombocytopenia 76 (8.2%) 105 (13.9%) 181 (10.7%) <0.001
(platelets <150x109/L) (n, %) 
Mean hemoglobin (SD) 13.0 (3.36) 13.8 (2.86) 13.4 (3.17) <0.001
Mean WBC count (SD) 8.5 (6.09) 9.5 (8.24) 8.9 (7.15) 0.004
Mean platelet 454.1 (269.42) 399.5 (267.21) 429.5 (269.72) <0.001
count (SD)
Laboratory
abnormalities (n, %) 206 (22.2%) 200 (26.3%) 406 (24%) 0.049
Prior thrombosis (n, %) 217 (20.4%) 200 (22.2%) 417 (21.2%) 0.34
Prior hemorrhage 55 (5.1%) 52 (5.7%) 107 (5.4%) 0.53
RBC transfusion 53 (4.9%) 67 (7.3%) 120 (6.0%) 0.02
requirements
WBC: white blood cell; RBC: red blood cell.
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MF being more prevalent in males (74.8% versus 61.7%;
P=0.01) and post-ET MF being more common in females
(21.7% versus 14.3%; P=0.01). Mean hemoglobin concen-
tration (13.8 versus 13.0 g/dL, P<0.001) and white blood
cell count (9.5 versus 8.5x109/L, P=0.004) were higher in
males whereas females had a higher mean platelet count
(454.1 versus 399.5x109/L, P<0.001). Thrombocytopenia
was more common in males (13.9% versus 8.2%,
P<0.001) whereas no differences were noted in the
prevalence of anemia or leukopenia (P>0.05).  Males
were also more likely to have a history of red blood cell
transfusion requirements (7.3% versus 4.9%, P=0.02).
Risk scores, language prevalence, history of prior throm-
bosis or hemorrhage did not differ by gender (all P>0.05).
Prior thrombosis was further stratified by gender and
MPN type: no differences were noted in ET (males
23.5% versus females 19.3%, P=0.156), PV (males 26.7%
versus females 29.8%, P=0.339) or MF (males 12.8% ver-
sus females 9.7%, P=0.298). Few differences were noted
between genders when comparing prior therapies, with
the exception of higher rates of phlebotomy/venesection
and givinostat/vorinostat use in males (both P<0.05;
Figure 1).
Symptoms of myeloproliferative neoplasms analyzed
by gender
After adjusting for MPN subtype and age, the overall
total symptom score was higher for females than males
[22.8 (SD=17.0) versus 20.3 (SD=16.3), P<0.001; Figure 2].
Females also had higher scores for all individual MPN
symptoms that met statistical significance (Figure 3).
These included fatigue (4.5 versus 4.0, P<0.001), early
satiety (2.6 versus 2.3, P=0.02), abdominal pain (1.6 versus
1.2, P=0.001), abdominal discomfort (2.1 versus 1.6,
P<0.001), headache (2.2 versus 1.6, P<0.001), concentra-
tion difficulties (2.7 versus 2.3, P=0.01), dizziness (2.5 ver-
sus 2.0, P<0.001), numbness (2.6 versus 2.2, P=0.001),
insomnia (3.4 versus 2.4, P<0.001), sadness (2.6 versus 2.3,
G.L. Geyer et al.
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Figure 1.  Percentage of MPN patients
who have received prior therapies (x
axis) compared by gender.
Figure 2. Distribution of MPN-SAF
scores according to age in females
(top) and males (bottom)  Evaluation of
total number of patients in each gender
(y axis) when compared by total MPN-
SAF TSS value (x axis).
P=0.01), night sweats (2.4 versus 2.0, P=0.002) and bone
pain (2.3 versus 1.6, P<0.001). Items that did not show
gender differences included inactivity, sexuality con-
cerns, cough, pruritus, fever, weight loss and overall
quality of life. Fatigue was the most severe symptom in
both genders. The prevalence of symptoms differed
between genders for many of the individual MPN items
(Figure 4). With the exception of weight loss (males
37.4% versus females 31.7%, P=0.008), the prevalence of
all symptoms that were statistically different between
females and males were higher in the former. These
symptoms included abdominal pain (46.0% versus
40.8%, P=0.02), abdominal discomfort (55.2% versus
50.7%, P=0.046), headache (58.1% versus 49.1%,
P<0.001), dizziness (61.0% versus 56.6%, P=0.046),
numbness (64.1% versus 58.1%, P=0.007), insomnia
(70.5% versus 59.9%, P<0.001), night sweats (55.6% ver-
sus 49.8%, P=0.01) and bone pain (53.2% versus 43.4%,
P<0.001).  
Symptoms of myeloproliferative neoplasms analyzed
by region/culture
The influence of region/culture was also explored
among male and female patients by comparing the
Chinese cohort (n=544) with the Western cohort consist-
ing of patients from Europe and the USA (n=1,462).
Overall, female Chinese patients expressed more severe
symptoms related to headaches (2.5 versus 2.0, P=0.01),
dizziness (3.1 versus 2.2, P<0.0001), problems with sexu-
ality (4.6 versus 2.9, P<0.0001), fever (0.6 versus 0.4,
P=0.005) and weight loss (1.6 versus 1.1, P=0.001) with a
higher total symptom score (22.2 versus 19.5, P=0.023)
and worse overall quality of life (3.1 versus 2.8, P=0.048;
Figure 5). Chinese females had higher scores for sexuali-
ty-related complaints (4.6/10) and insomnia (3.3/10). In
contrast, Western females described worse fatigue (4.7
versus 4.0, P=0.0003) and abdominal pain (1.7 versus 1.1,
P=0.0004). The highest scores for Western females were
for fatigue (4.7/10) and insomnia (3.4/10). 
Gender differences in MPN
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Figure 3.  Comparison of scores for the
individual items of the MPN-SAF
between males and females.
Figure 4. Comparison of the prevalence
of MPN-SAF symptoms between males
and females.
Like Chinese females, Chinese males also expressed
more severe symptoms related to headaches (1.9 versus
1.4, P=0.001), dizziness (2.6 versus 1.8, P<0.0001), sexual-
ity problems (4.5 versus 3.4, P=0.0001), fever (0.7 versus
0.4, P=0.0002) and weight loss (2.2 versus 1.1, P<0.0001)
(Figure 6) than their Western counterparts. The highest
scores for Chinese males were for sexuality concerns
(4.5/10) and fatigue (3.9/10). The same pattern was seen
for Western males, with the highest scores being for
fatigue (4.1/10) and sexuality concerns (3.4/10).
Discussion
The diversity of the various types of MPN has made
full characterization of their symptom profiles challeng-
ing. PV, ET and MF may concurrently shorten survival
and impair quality of life. For decades, gender differences
in MPN have been observed and documented but
remained of low investigational priority given the pauci-
ty of exploratory tools. Objective examination of symp-
tom heterogeneity has now emerged as a possibility fol-
lowing the development of MPN-specific PRO tools (MF-
SAF, MPN-SAF and MPN-10), enhanced precision of risk
scoring algorithms and advances in genomic sequenc-
ing.5,11,12 Applying many of these novel instruments, this
study represents the first large-scale investigation into
the correlates between gender, clinical features and
patients’ symptoms.
This investigation yielded a number of important find-
ings. The first is the observation that female patients
were more likely to have ET (48.6%) whereas males
were more likely to have PV (30.3%). This is consistent
with previous findings, with published data historically
supporting a prevalence of females among ET patients
and a prevalence of males among patients with PV.13-17
Gender discrepancies within hematologic malignancies
are not unique to MPN. Similar discordances in gender
prevalence have been demonstrated in other disorders
such as acute lymphoblastic leukemia, chronic lympho-
G.L. Geyer et al.
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Figure 5. Comparison of scores for indi-
vidual MPN-SAF items between
Chinese and Western females.
Figure 6. Comparison of scores for indi-
vidual MPN-SAF items between
Chinese and Western males.
cytic leukemia and multiple myeloma.18,19 Although the
etiological cause of this discordance remains unclear, sex
chromosome complement/aberrations/aneuploidy, an
influence of sex hormones, immune-competence, and
gene expression may all be potential contributors.20-23
Investigation of these factors was beyond the scope of
this study but they would be worth exploring in future
studies.
This study also found that males and females have
similar rates of thrombosis. Previous investigations
showed that thrombotic risk typically differs by sex
among the MPN subtypes.2,24-26 Within the ECLAP study,
female PV patients were more likely than males to suffer
thrombotic complications (11% versus 8%), particularly
within the splanchnic system.27 Similarly, multivariable
analysis of data from a recent international collaborative
study of 891 ET patients identified that only male gender
was predictive of venous thrombosis.28 Gender also
appears to influence the location of vascular events. A
recent investigation identified that women were more
likely to experience macrothrombosis within the abdom-
inal venous system (hepatic, portal, mesenteric or splenic
veins) whereas males were more likely to experience
events in the deep venous system, including limb throm-
bosis and pulmonary emboli.16
Although the influence of gender on the pathogenesis
of thrombosis remains unclear, mounting evidence sug-
gests that both the type and ratio of circulating sex hor-
mones plays an important role in the thrombotic cas-
cade. In an investigation involving exogenous sex-steroid
administration, ET patients exposed to hormone replace-
ment therapy (estrogen only) had similar rates of arterial
and venous thrombosis when compared to ET patients
not on therapy.29 Importantly, this finding conflicts with
studies of healthy populations in which females taking
hormone replacement therapy have been observed to be
at greater thrombotic risk. However, ET patients utilizing
oral contraceptive therapy (estrogen and progesterone
combined) had increased rates of venous thrombosis,
and specifically, a 5-fold increased risk of splanchnic
venous thrombosis (15% versus 3%). From a hormonal
standpoint, it remains unclear why male ET patients
seem to face a higher risk of thrombosis than females,
but this serves to show that the pathogenesis is likely
multifactorial. We have no explanation for why males
and females in our specific study population had similar
rates of thrombosis, independently of MPN subtype. It
should be noted that neither the location nor the type of
thrombosis (arterial versus venous) was recorded in this
study, and we suspect this information might have shed
some light on our discrepant finding.
We found it interesting that despite not differing by
total number of thrombotic events, our female popula-
tion still described more abdominal pain.  Given that this
study utilized reported events only (and did not prospec-
tively investigate for thrombosis), it is possible that some
female patients had unrecognized macrothrombosis in
the abdominal cavity, accounting for this symptom.
Alternatively, the discrepancy may be related to differ-
ences in spleen size, which were not investigated in this
study, or to differences in symptom expression, which
are discussed below. 
The observation that males and females reported dif-
ferent symptom burdens remains a major finding.
Overwhelmingly, females described symptoms with
greater frequency and severity than males. In particular,
abdominal complaints (abdominal pain, discomfort) and
microvascular symptoms (headache, fatigue, insomnia,
concentration difficulties, dizziness) dominated the
female symptom burden. Factors that might have
accounted for higher symptom scores (such as anemia,
high-risk disease status or increased counts of hemor-
rhagic/thrombotic complications) were not observed to
occur at higher rates in females. In fact, males were more
likely to have increased transfusion requirements
(despite describing less fatigue) and thrombocytopenia.
The underlying cause of our observations is, therefore,
uncertain. It is well recognized that the prevalence of
abdominal pain is higher among females.30 Irritable
bowel syndrome, a chronic constellation of abdominal
symptoms including pain, discomfort and alterations in
bowel habits, has been reported to occur in a female-to-
male ratio of 3:1 and remains a common source of
abdominal complaints in younger populations.31
However, the prevalence of irritable bowel syndrome
declines in individuals over 60 years old and given the
average age of MPN females, this syndrome is unlikely to
serve as a primary symptom driver. It is plausible that in
addition to having a higher risk of macrovascular events,
females also incur more microvascular events.
Microthrombosis contributes to microvascular symp-
toms (lightheadedness, dizziness, vertigo, concentration
problems, numbness/tingling and sexual dysfunction) by
compromising endothelial function and inducing local
hypoxia.32 In this study, females clearly described more
frequent and more severe microvascular symptoms than
did males. Mechanisms that may account for different
risks of microvascular dysfunction are worthy of further
exploration and may parallel those driving macrothrom-
bosis. Underreporting of microvascular symptoms by
males is also a potential explanation of our observations
and is discussed further below. Congruent with previous
investigations, males and females described similar
degrees of sexual dysfunction and fatigue remained the
most symptomatic facet of the disease burden.
Patients’ ethnicity and culture also appear to contribute
to symptom burden. Variations in symptom expression
were noted when Western and Eastern patients were
compared. Independent of gender, Chinese patients
described more microvascular symptoms (headaches,
dizziness) and more concerns related to sexuality. In con-
trast, fatigue was the most prominent symptom among
Western male and female patients. Variations between
MPN in Eastern and Western patients have been high-
lighted by the presence of fundamental biological and
clinical differences, which are being increasingly dis-
cussed in the literature.33,34 For example, Eastern patients
with MF are more likely to be younger and less likely to
struggle with constitutional symptoms or splenomegaly.
Survival differences between the two cohorts has also
been observed, with median survival being slightly
longer in patients of Chinese ethnicity. Given the subjec-
tivity inherent to symptom reporting, it remains unclear
whether the differences in MPN-SAF scores between
races are related to norms of cultural expression (espe-
cially willingness to verbalize problems related to sexual-
ity) or the natural outworking of true genotypic and phe-
notypic differences between races.
The possibility that our observations are related to
reporting discrepancies is also an important matter of
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discussion. Published data show that females tend to
describe more numerous and more intense symptoms
than males, independent of location or organ system
involved. In a study of 13,538 non-patient community
residents, participants evaluated the lifetime prevalence
of non-menstrual complaints and 20 of the 22 most com-
mon symptoms were reported more frequently by
females.35 Similarly, experimental studies involving
induction of pain have shown that females have a lower
threshold of pain tolerance and report more symptoms
than males.36 These findings may be driven by biological
differences in somatic and visceral sensation, sex-influ-
enced descriptiveness in symptom labeling and report-
ing, social acceptance of symptom revelation, sex-related
differences in the prevalence of depression and anxiety
and gender biases inherent to the research process. Some
studies have suggested that females engender greater
bodily vigilance, potentially as an innate mechanism to
optimize fertility.37,38 Other studies advocate that social
cues have impressed upon males the importance of lim-
iting expression of discomfort/illness, maintaining a stoic
appearance and underemphasizing complaints.39
Independently of the foregoing, we find it intriguing
that female MPN patients had the same quality of life
scores as males, despite having more frequent and severe
symptomatology. The literature supports health-related
quality of life as being typically rated lower among
females. This has traditionally been attributed to the
higher prevalence of disability and chronic conditions in
this population.40 However, in this study MPN-related
comorbidities were similar between the two sexes. It is
plausible that MPN females have socially adapted to
compensate for their intensified symptom burden.
Alternatively, female patients may simply be more dis-
posed to voice their complaints. We also note that
females described greater symptom burdens but their
risk scores were similar to those of the males. This infor-
mation corroborates the previous finding of the MPN
Symptom Burden study that MPN symptoms are not sur-
rogates for disease severity.4
It is important to recognize that there are a number of
limitations to this exploratory investigation. The first is
that the term ‘gender’ is being used synonymously with
genotypically-defined ‘sex’. As stated, the surveys allowed
patients to self-report their sex as either ‘male’ or ‘female’.
Although it may be assumed that the recorded choice
referred to genotypic makeup, it is possible that some
patients recorded their ‘gender identity’ instead, which
may not be synonymous with chromosomal makeup.
Should this have occurred, we believe that the number of
cases would have been small and likely consistent with the
prevalence of discordant associations in the community.
We also lack information on the exact location of events
(peripheral versus central) and note that males had greater
transfusion requirements than females despite similar rates
of anemia. We suspect that this is related to the averaging
of pre- and post-transfusion hemoglobin controls in males,
resulting in falsely high hemoglobin levels.  It is worth not-
ing that the majority of patients within this population of
MPN patients were classified as low to intermediate risk,
which potentially skews symptom burden towards lower
values. Although an evaluation of differences in symptom
burden between genders separated by risk category was
beyond the scope of this study, future investigations could
further explore this issue to determine whether symptom
progression differs between the sexes. It is important to
note that there are inherent flaws in using a ‘self-reporting’
format. However, we believe that the use of validated
MPN-specific PRO tools greatly improves the cogency of
the results. In addition, members of the clinical team were
primarily responsible for all data collection not related to
symptom expression, conceivably limiting errors in the
recording process. It is regrettable that underlying muta-
tions could not be analyzed, as doing so could have offered
yielded interesting information.
The concomitant development of innovative technolo-
gies and novel symptom assessment tools has revolution-
ized the treatment landscape for MPN. Few fields of
study can boast of a faster or more cooperative manner
via which pioneering research has translated into
improved outcomes for patients. In this study, we have
determined that gender integrally relates to disease fea-
tures and symptom burden. These results further under-
score the importance of considering each gender individ-
ually as treatment regimens are designed. Understanding
that males may be less likely to voice their MPN symp-
toms should influence clinicians to explore potentially
under-expressed complaints. Similarly, acknowledging
that females may have greater symptom burdens should
motivate healthcare providers to consider novel thera-
pies and explore trial options. This exploratory study
indicates the importance of including gender as a contrib-
utor to heterogeneity and as an object of investigation in
future studies.
G.L. Geyer et al.
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